Raymond James Financial Inc. Purchases 79,668 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Raymond James Financial Inc. increased its stake in Elanco Animal Health by 9.1%, totaling approximately $9.99 million in holdings.
• Institutional investors dominate Elanco's ownership, holding 97.48% of the company's stock, with notable investments from Nuveen LLC and Dimensional Fund Advisors LP.
• Elanco reported $0.26 earnings per share for the last quarter, surpassing expectations and showing a 4.8% annual revenue growth.

Raymond James Financial Inc. lifted its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 9.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 951,791 shares of the company's stock after purchasing an additional 79,668 shares during the quarter. Raymond James Financial Inc. owned about 0.19% of Elanco Animal Health worth $9,994,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Yousif Capital Management LLC purchased a new position in Elanco Animal Health in the first quarter worth $119,000. Wealth Enhancement Advisory Services LLC bought a new stake in Elanco Animal Health in the first quarter worth $111,000. SG Americas Securities LLC bought a new stake in Elanco Animal Health in the first quarter worth $891,000. GAMMA Investing LLC lifted its stake in Elanco Animal Health by 1,743.8% in the first quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock worth $130,000 after purchasing an additional 11,718 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Elanco Animal Health by 127.5% in the fourth quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock worth $1,179,000 after purchasing an additional 54,581 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ELAN has been the subject of several recent research reports. Piper Sandler boosted their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Zacks Research downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 20th. Finally, Stifel Nicolaus upped their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded down $0.09 during midday trading on Thursday, reaching $17.27. 2,152,026 shares of the company traded hands, compared to its average volume of 5,994,076. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of 20.08, a price-to-earnings-growth ratio of 3.41 and a beta of 1.62. The business has a 50 day moving average of $15.81 and a two-hundred day moving average of $12.83. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.87. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.